Distribuzione geografica
Continente #
NA - Nord America 2.660
EU - Europa 2.462
AS - Asia 1.014
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
SA - Sud America 4
AF - Africa 1
Totale 6.153
Nazione #
US - Stati Uniti d'America 2.649
CN - Cina 582
UA - Ucraina 533
SE - Svezia 379
GB - Regno Unito 363
IT - Italia 349
TR - Turchia 309
FR - Francia 276
IE - Irlanda 223
DE - Germania 163
FI - Finlandia 95
IN - India 93
BE - Belgio 51
CA - Canada 10
RU - Federazione Russa 10
IL - Israele 8
VN - Vietnam 8
EU - Europa 7
NL - Olanda 7
JP - Giappone 4
CL - Cile 3
NZ - Nuova Zelanda 3
PK - Pakistan 3
PL - Polonia 3
TW - Taiwan 3
AU - Australia 2
CH - Svizzera 2
DK - Danimarca 2
IR - Iran 2
RO - Romania 2
BR - Brasile 1
CZ - Repubblica Ceca 1
GR - Grecia 1
HK - Hong Kong 1
LU - Lussemburgo 1
MX - Messico 1
RS - Serbia 1
SC - Seychelles 1
SG - Singapore 1
Totale 6.153
Città #
Chandler 653
Jacksonville 610
Southend 264
Princeton 231
Dublin 223
Izmir 188
Nanjing 186
Beijing 116
Cambridge 101
Dearborn 101
Wilmington 90
Altamura 71
Ann Arbor 67
Boardman 61
Chieti 60
Nanchang 57
Brussels 47
Shenyang 47
Ashburn 38
Tianjin 29
Hebei 26
Woodbridge 26
Hangzhou 24
Kunming 23
Grevenbroich 21
Washington 21
Augusta 16
Jiaxing 15
Jinan 14
Norwalk 14
San Mateo 14
Pescara 13
Rome 13
Collecorvino 12
Ningbo 12
Orange 11
Milan 10
Changsha 8
Dong Ket 8
Latina 8
Montesilvano 8
Toronto 8
Auburn Hills 7
Falls Church 6
Helsinki 6
Lanzhou 6
Munich 6
Varallo 6
Fairfield 5
Leawood 5
Tappahannock 5
Hanover 4
Houston 4
Los Angeles 4
Zhengzhou 4
Andover 3
Cavacurta 3
Taizhou 3
Valduggia 3
Bari 2
Changchun 2
Clearwater 2
Eden Prairie 2
Edinburgh 2
Gent 2
Hyderabad 2
Islamabad 2
Karasawa 2
Macerata 2
Montréal 2
New Delhi 2
Pistoia 2
Saint Louis 2
San Vito Chietino 2
Selvazzano Dentro 2
Torino 2
Waanrode 2
Walnut 2
Anagni 1
Apo 1
Aquila 1
Aradeo 1
Ardabil 1
Basking Ridge 1
Belgrade 1
Brisbane 1
Castel Di Sangro 1
Cellino Attanasio 1
Chicago 1
Chongqing 1
Concordia Sagittaria 1
Corbetta 1
Council Bluffs 1
Denver 1
Easton 1
Empoli 1
Faisalabad 1
Fano 1
Fort Collins 1
Frankfurt 1
Totale 3.705
Nome #
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays 114
ALK protein analysis by IHC staining after recent regulatory changes: A comparison of two widely used approaches, revision of the literature, and a new testing algorithm 99
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors 94
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. 86
Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle 84
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. 80
A unique microRNA signature associated with ischemic stroke in humans 78
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 78
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 77
ATP-binding cassette transporter A1 (ABCA1) overexpression in hypercholesterolemic plaques: a potential molecular explanation 76
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 76
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment 76
Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. 75
A unique microRNA signature associated with plaque instability in humans. 74
ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm 74
ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: Results of the first italian external quality assurance scheme 74
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. 73
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. 73
AKT1(E17K) in human solid tumours 72
Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. 71
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation 71
Overexpression of ABCA1 in human plaques exposed to hypercholesterolemia: the role of microRNA modulation 70
Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control 70
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. 69
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. 69
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 69
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. 68
Detection of gene mutations on cytological specimens: clinical implications 68
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 68
The chromosomal location of the mouse mammary tumor gene Int6 and related pseudogenes in the mouse genome. 66
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. 65
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. 65
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 65
Survivin gene expression in early-stage non-small cell lung cancer. 64
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. 64
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. 63
Mutational profile of GNAQQ209 in human tumors. 63
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 63
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. 63
Enriched SSCP: a highly sensitive method for the detection of unknown mutations. Application to the molecular diagnosis of lung cancer in sputum samples. 62
Correspondence - In Reply - Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting 62
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. 62
Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. 61
Host genetic background effect on the frequency of mouse mammary tumor virus-induced rearrangements of the int-1 and int-2 loci in mouse mammary tumors. 61
null 61
Bronchioloalveolar carcinoma: K-ras mutations are constant events in the mucinous subtype 60
Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up 60
mdm2 gene alterations and mdm2 protein expression in breast carcinomas 60
microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer. 60
Lung tumours from non-smoking subjects: A p53-related genetic instability in a subset of cases. 59
p53 alterations in non-small cell lung cancer correlate with metastatic involvement of hilar and mediastinal lymph nodes 59
Stabilita’ del dna in campioni citologici conservati in fase liquida 59
Hypertension is a determinant of ABCA1 expression in atherosclerotic plaques from hypercholesterolemic patients 59
Reduction of atherothrombotic burden before stent deployment in non-ST elevation acute coronary syndromes: Reduction of myocardial necrosis achieved with nose-dive manual thrombus aspiration (REMNANT) trial. A volumetric intravascular ultrasound study 59
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy 59
The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas. 58
Telomerase Activity as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer 58
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies 58
mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. 57
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. 57
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. 57
ABCA-1 expression is reduced in atherosclerotic plaques from hypertensive patients: a new potential link between hypertension and atherosclerosis 57
Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. 56
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 56
Assessing EGFR mutations. 54
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 54
Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31. 54
Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. 53
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. 53
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. 53
Genetic analysis of lung tumors of non-smoking subject: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus 52
Hypertension modulates miR-145 expression in human atherosclerotic plaques 52
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. 51
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients 51
Evaluation of FHIT gene alterations in ovarian cancer 51
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 51
Telomerase activity as a prognostic indicator in Stage I Non- Small Cell Lung Cancer -Gruppo Italiano di Patologia Molecolare II Riunione Scientifica. Pisa 20-22 Giugno99 49
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. 49
Predictive markers in lung cancer: A few hints for the practicing pathologist 49
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 49
p53 mutations and histologic type of invasive breast carcinoma. A polymerase chain reaction-single-strand conformation polymorphism and immunohistochemical analysis. 48
Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. 47
p53 mutations and histological type of invasive breast carcinoma. 47
Reduced expression of INT-6/eIF3-p48 in human tumors. 46
Prostatic cancer: molecular bases. 46
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 46
Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations 46
p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. 45
Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. 44
Association between cigarette smoking and FHIT gene alterations in lung cancer. 44
Nucleotide and deduced amino acid sequences of tumor gene INT6. 43
Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. 43
Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. 43
p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. 43
Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. 41
p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study 39
Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. 39
Microsatellite alterations and p53, TGFbetaRII, IGFIIR and BAX mutations in sporadic non-small-cell lung cancer. 34
P53 and C-erbb-2 alterations in in-situ and invasive ductal breast carcinomas - a genetic and immunohistochemical analysis. 34
p53 nuclear accumulation in preneoplastic lesions and stage I uterine endometrioid adenocarcinoma. 33
Totale 6.020
Categoria #
all - tutte 18.269
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.269

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019439 0 0 0 0 0 24 108 19 12 4 3 269
2019/20201.366 431 98 18 46 87 80 149 121 30 139 156 11
2020/2021663 114 8 119 5 53 132 17 3 77 93 6 36
2021/2022603 18 7 8 131 31 23 13 38 50 33 84 167
2022/20231.743 144 216 70 212 193 345 115 112 236 14 47 39
2023/2024228 70 27 46 26 56 3 0 0 0 0 0 0
Totale 6.378